Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination

  1. Yukiya Kurahashi
  2. Koichi Furukawa
  3. Silvia Sutandhio
  4. Lidya Handayani Tjan
  5. Sachiyo Iwata
  6. Shigeru Sano
  7. Yoshiki Tohma
  8. Hiroyuki Ohkita
  9. Sachiko Nakamura
  10. Mitsuhiro Nishimura
  11. Jun Arii
  12. Tatsunori Kiriu
  13. Masatsugu Yamamoto
  14. Tatsuya Nagano
  15. Yoshihiro Nishimura
  16. Yasuko Mori

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1–52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron.

Article activity feed

  1. Version published to 10.1093/infdis/jiac178
  2. ScreenIT

    SciScore for 10.1101/2022.02.24.22271262: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Ethics: Our study was approved by the Ethics Committees of Kobe University Graduate School of Medicine (ID: B200200) and Hyogo Prefectural Kakogawa Medical Center.
    Consent: Written consent or the opt-out consent for our observational study was obtained.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power AnalysisSample size calculation was not performed.

    Table 2: Resources

    Antibodies
    SentencesResources
    We therefore compared the neutralizing antibody titers against D614G, Delta, Omicron in Term 1; we compared the titers against Alpha, Delta, Omicron in Term 2, and we compared those between Delta and Omicron in Term 3.
    D614G
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistical analyses were performed using STATA (ver. 14.2).
    STATA
    suggested: (Stata, RRID:SCR_012763)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.02.24.22271262 on medRxiv